Book Chapter


Book Chapter


Arthur E. Frankel, MD
Reference List

**Book Chapter**


**Book, Whole**


**In Press**

Arthur E. Frankel, MD
Reference List

In Press


Publications


April 19, 2012
Arthur E. Frankel, MD
Reference List

Publications

Agrawal V, Frankel AE. 14G2a anti-GD2 cross reactivity with the CD166 antigen. J Immunother 2010; 33: 1014-1015. 2010


R. Kandadi, Yinan Hua, Heng Ma, Qun Li, Shu-ru Kuo, Arthur E. Frankel, Jun Ren. Anthrax Lethal Toxin Suppresses Murine Cardiomyocyte Contractile Function and Intracellular Ca2+ Handling via a NADPH Oxidase-Dependent Mechanism. PLoS ONE. 2010; 5(10) e13335. 2010


Publications


Arthur E. Frankel, MD
Reference List

Publications


Articles


Arthur E. Frankel, MD
Reference List

Articles


Arthur E. Frankel, MD
Reference List

Articles


Frankel AE, Gillet D. Hormono- and immunotoxins for destroying cancer cells. Biofutur [276], 31-34. **2007**


Arthuro E. Frankel, MD
Reference List

Articles


Suh DY, Frankel AE. Advances in AML immunotherapy: The case for T-bodies. Leukemia Research 31[2], 127-128. 2007


Arthur E. Frankel, MD
Reference List

Articles


Hogge DE, Yalcintepe L, Wong SH, Gerhard B, Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clinical Cancer Research 12[4], 1284-1291. 2006

Hall PD, Sinha D, Frankel AE. Fresh frozen plasma and platelet concentrates may increase plasma anti-diphtheria toxin IgG concentrations: Implications for diphtheria fusion protein therapy. Cancer Immunology, Immunotherapy 55[8], 928-932. 2006


April 19, 2012
Arthur E. Frankel, MD
Reference List

Articles


Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 108[10], 3530-3537. 2006

Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunology, Immunotherapy 54[8], 799-806. 2005


Frankel AE. New anti-T cell immunotoxins for the clinic. Leukemia Research 29[3], 249-251. 2005

Frankel AE, Kreitman RJ. CLL immunotoxins. Leukemia Research 29[9], 985-986. 2005
Arthur E. Frankel, MD
Reference List

Articles


Hogge DE, Wong SH, Yalcintepe L, Frankel AE. The use of mouse models of normal and malignant hematopoiesis to design strategies for selective purging of primitive acute myeloid leukemia (AML) progenitors. Biology of Blood and Marrow Transplantation 11[2], 60. 2005


Wong L, Suh DY, Frankel AE. Toxin conjugate therapy of cancer. Seminars in Oncology 32[6], 591-595. 2005

Arthur E. Frankel, MD
Reference List

Articles

Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leukemia and Lymphoma 45[8], 1647-656. 2004


Frankel AE. Reducing the immune response to immunotoxin. Clinical Cancer Research 10[1 Pt 1], 13-15. 2004

Frankel AE, Gill PS. VEGF and myeloid leukemias. Leukemia Research 28[7], 675-677. 2004


Arthur E. Frankel, MD
Reference List

Articles

Hogge DE, Feuring-Buske M, Gerhard B, Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leukemia Research 28[11], 1221-1226. 2004

Jedema I, Barge RM, Frankel AE, Willemze R, Falkenburg JH. Acute myeloid leukemia cells in G0 phase of the cell cycle that are unresponsive to conventional chemotherapy are sensitive to treatment with granulocyte-macrophage colony-stimulating factor/diphtheria toxin fusion proteins. Experimental Hematology 32[2], 188-194. 2004

Liu TF, Urieto JO, Moore JE, Miller MS, Lowe AC, Thorburn A, Frankel AE. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Experimental Hematology 32[3], 277-281. 2004

Wong SH, Frankel AE, Hogge DE. Variant forms of human interleukin-3 (IL-3) linked to truncated diphtheria toxin (DT388), have enhanced cytotoxicity against acute myeloid leukemia (AML) progenitors. Blood 104[11], 498A. 2004


Articles

Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, Frankel AE. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expression and Purification 33[1], 123-133. 2004


Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria toxininterleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 17[1], 155-159. 2003

Frankel AE, Cohen KA, Hogge DE, Hall PD, Kreitman RJ. The AML recombinant toxin, DT(388)IL3, consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), shows safety at therapeutically active doses in cynomolgus monkeys. Blood 102[11], 386A. 2003


Arts hurb E. Frankel, MD
Reference List

Articles


Frankel AE, Neville DM, Bugge TA, Kreitman RJ, Leppla SH. Immunotoxin therapy of hematologic malignancies. Seminars in Oncology 30[4], 545-557. 2003


Liu TF, Tatter SB, Willingham MC, Frankel AE. Comparative study of growth factor receptor expression on human high grade gliomas and glioma cell lines. Clinical Cancer Research 9[16], 6127S. 2003

Arthur E. Frankel, MD
Reference List

Articles


Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leukemia Research 27[1], 79-84. 2003


Arthur E. Frankel, MD
Reference List

Articles


Frankel AE. Increased sophistication of immunotoxins. Clinical Cancer Research 8[4], 942-944. 2002


Frankel AE. Receptor upregulation enhances cell surface receptor targeted therapies. Leukemia Research 26[12], 1069-1071. 2002

Frankel AE. Receptor upregulation enhances cell surface receptor targeted therapies. Leukemia Research 26[12], 1069-1071. 2002

Frankel AE, Beran M, Hogge DE, Powell BL, Thorburn A, Chen YQ, Vallera DA. Malignant progenitors from patients with CD87+ acute myelogenous leukemia are sensitive to a diphtheria toxin-urokinase fusion protein. Experimental Hematology 30[11], 1316-1323. 2002
Arthur E. Frankel, MD
Reference List

Articles


Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer. Cancer Chemotherapy and Biological Response Modifiers 20, 301-313. 2002
Articles


Hall PD, Frankel AE. Reducing anti-DT IgG concentrations to improve the efficacy of a diphtheria fusion protein. Pharmacotherapy 22[10], 1355-1356. 2002


Hall PD, Razzouk BI, Willoughby TE, McLean TW, Frankel AE. The majority of children and adolescents with acute myeloid leukemia have detectable anti-DT388-GMCSF IgG concentrations, but at concentrations that should not preclude in vivo activity. Journal of Pediatric Hematology/Oncology 24[7], 521-526. 2002


Articles


Alexander RL, Ramage J, Kucera GL, Caligiuri MA, Frankel AE. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leukemia Research 25[10], 875-881. 2001


Arthur E. Frankel, MD
Reference List

Articles


Hall PD, Razzouk BI, McLean T, Willoughby TE, Frankel AE. The majority of children and adolescents with acute myeloid leukemia (AML) are candidates for diphtheria fusion toxin therapy. Blood 98[11], 213B. 2001

Hall PD, Virella G, Willoughby T, Atchley DH, Kreitman RJ, Frankel AE. Antibody response to DTGM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clinical Immunology 100[2], 191-197. 2001

Articles


Arts. E. Frankel, MD
Reference List

Articles


Arthur E. Frankel, MD
Reference List

Articles


Arthur E. Frankel, MD
Reference List

**Articles**

Frankel AE, Hall PD, Kreitman RJ. Steroid prophylaxis prevents systemic inflammatory response syndrome (SIRS) in AML patients treated with diphtheria fusion protein. Blood 94[10], 229B. **1999**


Hall PD, Virella G, Beckham W, Frankel AE. The majority of adult patients with acute myeloid leukemia (AML) have low to undetectable concentrations of antibodies against DTGM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte macrophage colony stimulating factor (GM). Blood 94[10], 64A. **1999**
Arthur E. Frankel, MD
Reference List

Articles


Hall PD, Kreitman RJ, Willingham MC, Frankel AE. DT388-GM-CSF, a fusion toxin targeting the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor, improves survival of SCID mice bearing human acute myeloid leukemia (AML) blasts over ARA-C. Blood 92[10], 615A. 1998

Hall PD, Kreitman RJ, Willingham MC, Frankel AE. Toxicology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony-stimulating factor (GM-CSF) in C57BL/6 mice. Toxicology and Applied Pharmacology 150[1], 91-97. 1998


Frankel AE, Fu T, Burbage C, Chandler J, Willingham MC, Tagge EP. IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor. Leukemia 11[1], 22-30. 1997

Reference List

**Articles**


Hall PD, Kreitman RJ, Willingham MC, Frankel AE. Pharmacology and toxicology of DT388-GMCSF, a fusion toxin consisting of a truncated diphtheria toxin linked to granulocyte-macrophage colony stimulating factor (GM-CSF). Blood 90[10], 3828. **1997**


Chandler JC, Frankel AE, Tagge EP. Genetic engineering of immunotoxins. Seminars in Pediatric Surgery 5[3], 206-211. **1996**
Articles


Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham M. Characterization of a ricin fusion toxin targeted to the interleukin-2 receptor. Protein Eng 9[10], 913-919. 1996

Frankel AE, Burbage C, Fu T, Tagge E, Chandler J, Willingham MC. Ricin toxin contains at least three galactose-binding sites located in B chain subdomains 1 alpha, 1 beta, and 2 gamma. Biochemistry 35 [47], 14749-14756. 1996

Articles


Fu T, Burbage C, Tagge E, Chandler J, Willingham M, Frankel AE. Double-lectin site ricin B chain mutants expressed in insect cells have residual galactose binding: evidence for more than two lectin sites on the ricin toxin B chain. Bioconjugate Chemistry 7[6], 651-658. 1996


Arthur E. Frankel, MD
Reference List

Articles


Articles


Willingham MC, Brothers TE, Tagge DU, Frankel AE. Endothelial Apoptosis in Immunotoxin-Induced Vascular Leak Syndrome - An In-Vitro Model. Laboratory Investigation 72[1], A36. 1995


Articles


Frankel AE. Immunotoxin therapy of cancer. Oncology (Williston.Park) 7[5], 69-78. 1993

Kim Y, Mlsna D, Monzingo AF, Ready MP, Frankel AE, Robertus JD. Structure of a ricin mutant showing rescue of activity by a noncatalytic residue. Biochemistry 31[12], 3294-3296. 1992

Olsnes S, Frankel AE. Genetically engineered toxins in perspective. Targeted Diagnosis and Therapy 7, 465-477. 1992

Li BY, Frankel AE, Ramakrishnan S. High-level expression and simplified purification of recombinant ricin A chain. Protein Expression and Purification 3[5], 386-394. 1992
Arthur E. Frankel, MD
Reference List

Articles


Oeltmann TN, Frankel AE. Advances in immunotoxins. FASEB Journal 5[10], 2334-2337. 1991


 Articles


Articles

Frankel AE, Welsh PC, Withers DI, Schlossman DM. Immunotoxin preparation and testing in vitro. Targeted Diagnosis and Therapy 1, 225-244. 1988


Arthur E. Frankel, MD
Reference List

Articles


Linsley PS, Ochs V, Laska S, Horn D, Ring DB, Frankel AE, Brown JP. Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients. Cancer Research 46[10], 5444-5450. 1986

Bogden AE, Frankel AE, Chong KT, Winkelhake J. Human-Tumor Xenograft Responses to Immunoconjugates in Parallel Subcutaneous (Sc) and Subrenal Capsule (Src) Assays. Proceedings of the American Association for Cancer Research 26[MAR], 287. 1985


Frankel AE. Antibody-toxin hybrids: a clinical review of their use. Journal of Biological Response Modifiers 4[5], 437-446. 1985


Arthur E. Frankel, MD
Reference List

Articles


Fawcett HD, Lantieri RL, Frankel AE, McDougall IR. Differentiating hepatic abscess from tumor: combined 111In white blood cell and 99mTc liver scans. AJR.American Journal of Roentgenology 135[1], 53-56. 1980


Frankel AE, Fischinger PJ. Rate of divergence of cellular sequences homologous to segments of Moloney sarcoma virus. Journal of Virology 21[1], 153-160. 1977
